PharmaTelevision - Konstantinos Karachalios from the European Patent Office talks about improving transparency in the patent system

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Konstantinos Karachalios from the European Patent Office talks about improving transparency in the patent system

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Konstantinos Karachalios from the European Patent Office

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Konstantinos's Role and responsibilities within Public policy issues at EPO

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at the LESI Conference in London, 2011. On this show I have Konstantinos Karachalios, who is from the European Patent Office and you are responsible for Public Policy Issues, welcome to the show.

Konstantinos Karachalios:

Thank you.

Fintan Walton:

First of all just Konstantinos, can we just ask you a little bit about your role within Public Policy Issues at the European Patent Office, what is that role?

Konstantinos Karachalios:

Yes, first of all is what are Public Policy Issues which are IP related and why affordity like the EPO engage it to this field. It started several years ago we did a very decent work which we called the scenario for the future and we tried to look at the context outside the patent system, what is the impact of the patent system in society and what might be let's say important changes in the associated context by impact of the patent system in the long-term. You know it's a very decent exercise and there we have identified issues and then we asked ourselves what are we going to do with this, this is the knowledge that we have just waiting that things happen or are we going to act, and then there step-by-step we developed activities and the framework which enable us to be proactive this is a reason why I am also here then giving a speech later and there are some nice examples what the patent system can do actively to diffuse tensions which are not necessary, which come from lack of knowledge, lack of evidence, lack of data and I think with all of this not only process but also the society at large.

Fintan Walton:

Sure, so in other words you are assisting the European Patent Office to identify those issues that will make the patent system much more transparent, much easier to use and overcome those obstacles that individuals would find or companies would find when dealing with the European Patent Office, would that be correct?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Konstantinos Karachalios

Senior Officer

Konstantinos Karachalios has worked at the European Patent Office since 1987. Head of the International Academy from 1999-2000; Manager of the Project for Africa and the Middle East in the Directorate for International Technical Co-operation, 2000-2004. Since 2004 active in the field of External Relations, with focus on Public Policy Issues, i.e. the big challenges that may impact the future of the patent system: governance of knowledge regimes, accessibility and transparency issues (related to climate change technologies, essential drugs, food security, ICT standards etc), emergence of new technologies (biotechnology and gene-technology, nanotechnology, clean energy etc.). Scenarios analyst, co-editor of the book "Scenarios for the Future: How might IP regimes evolve by 2025? What global legitimacy might such regimes have?" As initiator and coordinator of the international project between EPO, UNEP and ICTSD on IP and Climate change, he is EPO's Contact Person and Head of Delegation in the UNFCCC.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

European Patent Office

The European Patent Office is one of the two organs of the European Patent Organization (EPOrg), the other being the Administrative Council. The EPO acts as executive body for the Organization while the Administrative Council acts as its supervisory body as well as, to a limited extent, its legislative body. The actual legislative power to revise the European Patent Convention lies with the Contracting States themselves when meeting at a Conference of the Contracting States. Within the European Patent Office, examiners are in charge of studying European patent applications, filed by applicants, in order to decide whether to grant a patent for an invention. The patents granted by the European Patent Office are called European patents.